Founder and Chief Executive Officer
Laxminarayan Bhat is the Founder and Chief Executive Officer of Reviva Pharmaceuticals, Inc. Dr. Bhat has over 18 years of experience in drug discovery and development in the areas of central nervous system (CNS), cardiovascular (CV), metabolic diseases and cancer chemotherapeutics. Dr. Bhat has extensive research experience in design and development of prodrugs and softdrugs to improve the ADME-Tox properties of drug molecules. Dr. Bhat has a rich experience in nutrient transporter assisted drug delivery to improve the target selectivity and oral bioavailability of drugs.
Prior to founding Reviva, Dr. Bhat held research positions at XenoPort and ARYx Therapeutics in California. In 1997, Dr. Bhat joined Higuchi Biosciences Center's Drug Discovery Program at the University of Kansas and there he spent over two years as a Research Fellow. Dr. Bhat received post-doctoral training from the University of Gottingen in Germany and the University of Maine in France. In 1995, Dr. Bhat was selected for the Alexander von Humboldt fellowship, an internationally recognized prestigious award for a young scientist to pursue advanced research in Germany. Dr. Bhat holds a Ph.D. degree in synthetic organic chemistry. Dr. Bhat has authored over 15 research papers published in peer-reviewed scientific journals and is an inventor on more than 100 patents.
Chief Medical Officer
Dr. Cantillon brings over 17 years drug development experience in NIH, academia and pharmaceutical industry with roles of increasing responsibility and scope at AstraZeneca, Sanofi-Aventis, Wyeth/Pfizer, Schering-Plough/Merck Sharp & Dohme Corp, and consultancy for pharmaceutical, biotech and venture investment firms. Dr. Cantillon has expertise in translational Proof-of-Mechanism (POM), Proof-of-Concept (POC) and Phases I through IV trials and development in diverse therapeutic areas, but core expertise in the central nervous system as anesthesiology, neurology, and psychiatry. He is a board certified by American Board of Neurology and Psychiatry in psychiatry and geriatrics. Dr. Cantillon has extensive global clinical trial and successful regulatory experience. He has Initiated and built collaborative strategic partnerships as Coalition for Major Diseases CAMD, QIBA DCE-MRI and FDG-PET steering committees of RSNA, ADNI, Parkinson's Progression Markers Initiative, Michael J. Fox Foundation and International Society to Advance Alzheimer Research and Treatment. Dr. Cantillon is an author/coauthor of over 35 research articles published in the peer reviewed journals and two books.
Vice President, Regulatory Affairs & Product Development
Dr. Kanekal has over 20 years of pharmaceutical industry experience with board-certifications in Regulatory Affairs and Toxicology. He is a veterinarian with a Ph.D. in Pharmacology and Toxicology from the University of California at Davis and has conducted post-doctoral research at the School of Pharmacy at University of Texas in Austin. He is a veteran in Regulatory Strategy, Safety Assessment and Drug Development of both small molecules and biologics including reformulated drugs. He has a track record of rapidly moving early-stage drugs into clinical development and eventual NDA and market approval. He has managed non-clinical programs for numerous drugs and was responsible for several IND/NDA/BLA approvals such as Bexxar®, Treanda® and Synribo®. He has participated in many meetings with FDA and including advisory committee meetings. He was previously with Matrix Pharmaceuticals, Novartis (Chiron), GSK (Corixa), Teva (Cephalon, Salmedix, Chemgenex) and Astex (Supergen).